Corinne joined OXGENE in 2017 and after a brief period working as Molecular Biology Scientist, moved onto cell line engineering, developing cell line platforms with enhanced characteristics for viral vector manufacture (rAAV, LVV, AdV). As a group leader of viral cell line development, Corinne continues to optimize solutions for both commercial and internal R&D projects, the main focus being development of lentivirus packaging and producer cell lines.
Prior to OXGENE, Corinne gained extensive experience in molecular biology, protein purification and immunoassays working in both academia and industry settings. Corinne holds a bachelor's degree from Universita’ degli studi dell’Aquila and a master's degree from Universita’ Politecnica delle Marche (Italy).
About this event:
Date: July 14, 2022
11 am ET | 5 pm CET
11 am PT | 2 pm ET
Duration: 15 minutes
Lentiviral (LV) vectors have significant potential for cell and gene therapy applications. CAR-T and TCR therapies are becoming established treatments for blood malignancies that don’t respond to current therapies, and novel research aims to also exploit the usage of LV vectors to target solid tumors.
However, challenges remain within the LV vector manufacturing process, such as achieving scalability and robustness. These challenges contribute to the high costs of treatments and burdens for healthcare systems and patients.
OXGENE aims to develop technologies which address the challenges of LV vector manufacture, enabling innovators to help patients gain access to life-changing therapies. We have successfully established a technology to transition from 4-plasmid transfection to a fully stable, transfection-free, producer cell line using the same 4-plasmid set and HEK293 suspension host cell line as the transient system.
In this webinar, you will learn about:
The need for robust and scalable manufacturing platforms for lentiviral manufacture.
How OXGENE’s transfection-free producer cell line offers high, reproducible yields and scalability.
The steps involved with easy transition from transient to stable manufacturing platforms.